Association of Pneumococcal Conjugate Vaccine Use With Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older With and Without Medical Conditions, 2014 to 2017
Open Access
- 1 January 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Internal Medicine
- Vol. 183 (1) , 40-47
Abstract
Introducing the pneumococcal conjugate vaccine for use among children has been associated with significantly reduced incidence rates of pneumococcal disease, not only among children who were directly targeted for vaccination, but also among older children and adults who were not targeted for vaccination, by preventing the transmission of vaccine-type pneumococci.1 Three years after the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced among US children in 2013, the incidence of invasive pneumococcal disease, defined as identification of pneumococcus from a normally sterile site, declined by 58% to 72% among US adults.2 In 2014, the Advisory Committee on Immunization Practices (ACIP) recommended routine use of PCV13 in series with a dose of 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all US adults 65 years or older.3 This recommendation was supported by findings from a large randomized clinical trial in adults 65 years or older in the Netherlands (CAPITA trial) that reported that PCV13 provides protection not only against invasive pneumococcal disease (75% vaccine effectiveness [VE]), but also against vaccine-type noninvasive pneumococcal pneumonia, defined as pneumonia with no identification of pneumococcus from a normally sterile site (45% VE).4 In adults, pneumococcal pneumonia contributes the largest proportion of pneumococcal disease burden. The reported efficacy against the first episode of all-cause community-acquired pneumonia from this trial was 5.1% (95% CI, −5.1 to 14.2). However, continued PCV13 use among children was expected to be associated with further reduced remaining burden of adult pneumococcal disease that was associated with serotypes contained in PCV13 and decrease the effectiveness of PCV13 in preventing pneumococcal disease in adults. Routine PPSV23 use for US adults 65 years or older had been recommended since 1984, but data on PPSV23 effectiveness against noninvasive pneumococcal pneumonia were considered to be inconsistent.3Keywords
This publication has 22 references indexed in Scilit:
- Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort studyBMC Infectious Diseases, 2018
- Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case–control study in a 2-year prospective cohortBMJ Open, 2018
- Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in AdultsNew England Journal of Medicine, 2015
- Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillanceThe Lancet Infectious Diseases, 2015
- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged ≥65 Years: Recommendations of the Advisory Committee on Immunization Practices (ACIP)2014
- Use of vaccines as probes to define disease burdenThe Lancet, 2014
- U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal VaccinationNew England Journal of Medicine, 2013
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Coding Algorithms for Defining Comorbidities in ICD-9-CM and ICD-10 Administrative DataMedical Care, 2005
- Adapting a clinical comorbidity index for use with ICD-9-CM administrative databasesJournal of Clinical Epidemiology, 1992